Skip to main content

Valorization Team (together with DCVA)

Margien Boels
Impact Officer DCVA

Margien Boels

Profile

Margien Boels is an Impact Officer at the Dutch Cardiovascular Alliance (DCVA), where she’s responsible for the commercialization & valorization of DCVA consortia into solutions for patients and scalable biomed start-ups. She obtained a master’s degree in Nutrition and Health from Wageningen University and continued her academic career pursuing a Ph.D. degree in Medicine from Leiden University Medical Center in 2016 with the project “The glomerular endothelial glycocalyx in diabetic nephropathy, as part of a consortium of the Dutch Kidney Foundation. Later one, she worked as a stakeholder manager and as a Medical affairs Manager for Nutricia Nederland Medical.

Rob de Ree
DCVA Chair of valorization and Operating Partner BioGeneration Ventures

Rob de Ree

Profile

Rob de Ree is Chair of valorization at the Dutch Cardiovascular Alliance (DCVA), co-manager along RegMed XB of FIRST, a joint early phase investment fund. Rob started his career in pharma in 1991 in sales and marketing at the cardiovascular division of Byk Gulden. Rob joined Medtronic in 1996 where he worked in various sales and marketing roles, and then he moved to Crucell where he led the licensing business after which he joined BMEYE, a startup in hemodynamic monitoring where he serves as CEO until it was sold to Edwards Lifesciences.

Rob was subsequently CEO of Dezima Pharma, which was sold to Amgen in October 2015. Currently, Rob is operating partner at Biogeneration Ventures since 2016, serving on the board and in interim management positions in the fund’s portfolio companies. In addition, he is CEO of NorthSea Therapeutics and serves on the board of Mellon Medical.

Nazma Ilahibaks
Impact Officer RegMed XB

Nazma Ilahibaks, PhD

Profile

Nazma is a business developer holding a Ph.D. in Regenerative Medicine from Utrecht University. She is driven to bring novel technologies to the patient through venture building. Her experience as a scientist and business developer uniquely positions her to foster valorization within the field of regenerative medicine. Why Nazma is devoted to our mission: "I've always been motivated to create biomedical solutions for patients. This passion underpins my work at RegMedXB, where I help transform promising discoveries into solutions that benefit patients."

Dominique de Jong
Impact Officer RegMed XB

Dominique de Jong

Profile

With a broad academic background in biomedical sciences, engineering, and business, Dominique works to bridge the gap between academia and industry. Dominique thrives on innovation and connecting with brilliant minds pushing the boundaries of human knowledge.
With an investor-like mindset, Dominique analyses research projects and helps develop a translational strategy for early-stage innovations to attract investments and progress toward the clinic.
Optional: In her free time, you will find Dominique performing with her band, or planning her next trip.
Why Dominique is passionate about our mission: Too often, great science does not reach the patient. To truly create an impact, academia and industry need to come together. At RegMed XB, we are building an ecosystem to facilitate just that.